⬀ Loading…

GLAND · Back to the company page

Investment Brief

Evidence through Sep 2026

The business

Customers are innovators and specialty pharmaceutical companies in regulated markets; US revenue for the half-year was β‚Ή2,161 crore, up 37%, Europe and other regulated markets revenue was β‚Ή411 crore, up 23%, rest-of-world revenue was β‚Ή204 crore and India revenue was β‚Ή38.7 crore.

Revenue Β· Sep 2026
β‚Ή1,834 cr
β–² 23.3% vs a year ago
EBITDA Β· Sep 2026
β‚Ή484 cr
β–² 54.1% vs a year ago
Profit after tax Β· Sep 2026
β‚Ή291 cr
β–² 58.2% vs a year ago
EBITDA margin Β· trailing 12 months
27.2%
Price-to-earnings Β· trailing 12 months
44.5x
Promoter holding Β· Sep 2026
45.8%
βˆ’6.0 pp vs Jun 2026

What is changing

  • CDMO revenue grew 31% year-on-year to β‚Ή823 crore and contributed about 45% of total revenue, driven by commercial supply of previously signed contracts, new launches and new development and manufacturing partnerships.
  • US revenue grew 42% year-on-year to β‚Ή1,180 crore in the quarter and 37% to β‚Ή2,161 crore in the half-year, helped by new product launches and newer CDMO business.

Recent events

In Sep 2026, promoter holding fell by 6.0 percentage points versus the previous quarter.
On 4 Sep 2026, Fosun Pharma Industrial Pte. Ltd. disclosed a disposal of 6.0% of the company.

Catalysts

CatalystTimingSizeWhat has to go right
US FDA inspection of the additional bag manufacturing line, after which products from the line could be commercialized and the capacity constraint eased.β€”β€”The inspection has to conclude so that the line can be used for commercial supply.
NUPCO tender results from Saudi Arabia, which management says are delayed.β€”β€”The tender has to be announced; management says it has participated with about 13 products and is confident of winning products in that segment.

Strengths

  • CDMO growth and mix
    CDMO revenue grew 31% year-on-year to β‚Ή823 crore and contributed about 45% of total revenue, with margins described as better than the regular business by about 5% to 10%.
  • US portfolio expansion
    The company launched products in the US in the quarter, filed 11 ANDAs and received 10 approvals, bringing cumulative US ANDA filings to 399 with 350 approved and 49 pending.

Risks

  • Capacity constraints
    Management says it is struggling for capacity in ophthalmic, bags and liquid vials, with liquid vial utilization already at 92% and anticipated at close to 102% next year.
  • Tender and supply timing
    Performance was impacted by market-specific supply and tender dynamics, especially the delay of NUPCO tender results from Saudi Arabia, and by lower volumes due to delayed tender business in the Middle East.

Competitive position

On operating margin, the company's 27.3% is above the peer median of 13.5% for the 241 companies in the peer group with a value, ranking 37 of 241.

MetricGLANDPeer medianRank
Operating margin27.3%13.5%37 of 241
Return on capital employed15.1%12.5%97 of 242
Return on equity10.7%10.5%115 of 236

Compared with 248 companies in Pharmaceuticals & Biotechnology (medians; data as of 15 Nov 2026). Rank 1 is best, except price multiples, where 1 is lowest.

Latest quarter

Sep 2026Latestvs year agovs prior quarter
Revenueβ‚Ή1,834 cr23.3%1.9%
EBITDAβ‚Ή484 cr54.1%-1.0%
Profit after taxβ‚Ή291 cr58.2%-8.2%
  • Over the trailing twelve months revenue was β‚Ή7,072 crore, EBITDA was β‚Ή1,921 crore and profit after tax was β‚Ή1,236 crore, an EBITDA margin of 27.2%.

What the price requires

Market capitalisation β‚Ή55,016 cr Β· trailing 12-month profit after tax β‚Ή1,236 cr Β· price-to-earnings 44.5x

Assumed yearly return to shareholdersProfit needed at the endImplied yearly profit growth
12.0%β‚Ή1,737 cr12.0%

A calculation, not a forecast: 3-year horizon, the multiple unchanged and a constant share count.

Ownership and deals

HolderSep 2026Jun 2026Change
Promoters45.8%51.8%βˆ’6.0 pp
Foreign institutions10.4%8.7%+1.6 pp
Domestic institutions33.2%30.4%+2.8 pp
  • On 4 Sep 2026, Fosun Pharma Industrial Pte. Ltd. disclosed a disposal of 6.0% of the company.
Premium adds the bottom line, every strength, risk and catalyst with its sources, the guidance-versus-actuals section where it applies, and the full calculation set. Log in or see Premium

Facts from company filings, exchange data and company documents, with calculations shown. Educational information; not investment advice.

πŸ“Š Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagineβ„’ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
πŸ“Š Explore The Finmagineβ„’ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers β€” Please read without fail.

Investment Risk:
Investing in securities, including equities and mutual funds, involves inherent risks, including the potential loss of principal. All investments are subject to market fluctuations, regulatory changes, and other risks that may affect their value. Past performance is not indicative of future results. This report is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This report does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a SEBI-registered investment adviser or other qualified financial professional before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities or financial instruments discussed in this report. Any such positions, if material, are disclosed to the best of the author's knowledge and are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company, institution, or third party.

Information Sources:
The analysis and opinions expressed herein are based on publicly available information, including but not limited to company filings with the BSE/NSE, annual reports, management commentary, investor presentations, data from the Reserve Bank of India (RBI), SEBI, industry publications, and other reliable financial data sources. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This report may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. The author does not undertake any obligation to update such statements in the future.

Regulatory Compliance:
This report is intended to comply with the Securities and Exchange Board of India (Research Analysts) Regulations, 2014, as amended, and other applicable Indian laws and regulations.

Limitation of Liability:
The content of this report is provided "as is" without any warranties, express or implied, including accuracy, completeness, merchantability, or fitness for a particular purpose. The author and publisher expressly disclaim any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.